Wyeth controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile4 entries
2005
Dispute over compounded bioidentical hormones
Wyeth petitioned the FDA to take action against unlicensed compounded bioidentical hormone-replacement products, arguing that they lacked the clinical evidence and regulatory authorization required for approved medicines. The action reflected a broader commercial and regulatory dispute over competing forms of hormone therapy.
2002
Hormone-replacement therapy safety controversy
Women's Health Initiative results associated long-term estrogen-progestin hormone therapy with increased risks of stroke, heart attack, blood clots, and breast cancer. Wyeth terminated the affected trials early and saw substantial declines in Premarin, Prempro, and related sales.
1997
Fen-phen and fenfluramine safety controversy
The FDA requested withdrawal of fenfluramine after reports of deaths and serious health problems associated with the fen-phen diet-drug combination. The episode became one of Wyeth's most prominent product-safety controversies and contributed to heightened scrutiny of pharmaceutical appetite suppressants.
Pharmaceutical-waste and steroid-contamination controversy
European health authorities attributed illegal-steroid contamination in the food supply to fraudulent handling and disposal of pharmaceutical waste, including waste from synthetic progesterone production at a Wyeth facility. The episode raised environmental, supply-chain, and regulatory concerns.